Join
Live feed
·
PRReleasevia Quantisnow
Artelo Biosciences Inc. logo

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

ByQuantisnow·Wall Street's wire, on your screen.
ARTL· Artelo Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARTL (Artelo Biosciences Inc.) and more on Quantisnow.